Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 14,609 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10. Following the completion of the sale, the chief marketing officer owned 14,609 shares in the company, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, May 14th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $31.26 on Friday. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average price is $25.92 and its 200-day moving average price is $35.67. Maze Therapeutics, Inc. has a 52 week low of $10.98 and a 52 week high of $53.65. The stock has a market cap of $1.73 billion, a P/E ratio of -12.36 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Truist Financial dropped their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Wedbush increased their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $66.00.

Institutional Trading of Maze Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter valued at $39,000. Ameritas Investment Partners Inc. increased its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics in the 4th quarter worth $43,000. Finally, Russell Investments Group Ltd. raised its holdings in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.